Cost-effectiveness of a behavioral intervention for seropositive youth

AIDS Education and Prevention

Volumn 17, Issue 2, 2005, Pages 105-118

  Lee, Martha B ^a   Leibowitz, Arleen ^a   Rotheram Borus, Mary Jane ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE POLICY; HEALTH EDUCATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; METHODOLOGY; QUALITY OF LIFE; SERODIAGNOSIS; SEXUAL BEHAVIOR; SEXUAL EDUCATION; SEXUALITY;

ADOLESCENT; BEHAVIOR THERAPY; COST-BENEFIT ANALYSIS; DISEASE TRANSMISSION, HORIZONTAL; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; SEXUAL BEHAVIOR;

EID: 18044384223     PISSN: 08999546     EISSN: None     Source Type: Journal    
DOI: 10.1521/aeap.17.3.105.62906     Document Type: Article

References (24)

1. Abma, J.C., & Sonenstein, F.L. (2001). Sexual activity and contraceptive practices among teenagers in the United States, 1988 and 1995. National Center for Health Statistics. Vital Health Statistics, 23(21), 1-79.
2. Blackard, J.T., Cohen, D.E., & Mayer, K.H. (2002). Human immunodeficiency virus superinfection and recombination: Current state of knowledge and potential clinical consequences. Clinical Infectious Diseases, 34(8), 1108-1114.
3. Brookmeyer, R., & Gail, M.H. (1994). AIDS Epidemiology: A quantitative approach. Oxford, England: Oxford University Press.
4. Centers for Disease Control and Prevention. (2002). Young people at risk: HIV among America's youth. Retrieved May 7, 2003, from: http://www.cdc.gov/hiv/ pubs/facts/youth.ht m
5. Crepaz, N., & Marks, G. (2002). Towards an understanding of sexual risk behavior in people living with HIV: A review of social, psychological, and medical findings. AIDS, 36(2), 135-149.
6. Emini, E. A., Schleif, W. A., Deutsch, P., & Condram, J.H. (1996). In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds. Advances in Experimental Medicine and Biology, 394, 327-331.
7. Holtgrave, D.R., & Pinkerton, S.D. (1997). Updates of cost of illness and quality of life estimates for use in economic evaluation of HIV prevention programs. Journal of Acquired Immune Deficiency Syndromes, 16, 54-62.
8. Meyer-Bahlburg, H.F.L., Ehrhardt, A.A., Exner, T.M., & Gruen, R.S. (1988). Sexual risk behavior assessment schedule-Youth. New York: Columbia University, Department of Psychiatry College of Physicians and Surgeons.
9. Miller, L.G., Simon, P.A., Miller, M.E., Long, A., Yu, E.I., & Asch, S.M. (1999). High-risk sexual behavior in Los Angeles: Who receives testing for HIV? Journal of Acquired Immune Deficiency Syndromes, 22(5), 490-497.
10. Pinkerton, S.D., & Abramson, P.R. (1993). Evaluating the risks: A Bernoulli process model of HIV infection and risk reduction. Evaluation Review, 17, 504-528.
11. Pinkerton, S.D., & Abramson, P.R. (1998). The Bernoull-process model of HIV transmission: Applications and implications. In D.R. Holtgrave (Ed.), Handbook of economic evaluation of HlV prevention programs (pp. 13-32). New York: Plenum Press.
12. Pinkerton, S.D., & Holtgrave, D.R. (1997). Lifetime costs of HIV/AIDS medical care. Journal of Acquired Immune Deficiency Syndromes, 14(4), 380-382.
13. Pinkerton, S.D., & Holtgrave, D.R. (1998). A method for evaluating the economic efficiency of HIV behavior risk reduction interventions. AIDS and Behavior, 2, 189-201.
14. Pinkerton, S.D., Martin, J.N., Roland, M.E., Katz, M.H. Coates, T.J., & Kahn, J.O. (2004). Cost-effectiveness of HIV post-exposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS, 18, 1-19.
15. Rotheram-Borus, M.J., Lee, M.B., Murphy, D.A., Futterman, D., Duan, N., Birnbaum, J., et al. (2001). Efficacy of a preventive intervention for youth living with HIV. American Journal of Public Health, 91, 400-405.
16. Rotheram-Borus, M.J., Lee, M., Zhou, S., O'Hara, P., Birnbaum, J.M., Swendeman, D., et al. (2001). Variation in health and risk behaviors among youth living with HIV. AIDS Education and Prevention, 13, 42-54.
17. Salgo, M.P., Beattie, D., Bragman, K., Donatacci, L., Jones, M., Montgomery, L., et al. (1996, July). Saquinavir (Invirase) vs. hivid (Zalcitabine) vs. combination as treatment for advanced HIV infection in patients discontinuing/unable to take retrovir (Zidovudine) [Abstract Mo.B.410]. Paper presented at the 11th International Conference on AIDS, Vancouver, British Columbia, Canada.
18. Scheer, S., Chu, P.L., Klausner, J.D., Katz, M.H., & Schwarcz, S.K. (2001). Effect of highly active antiretroviral therapy on diagnoses of sexually transmitted diseases in people with AIDS. The Lancet, 357(9254), 432-435.
19. Seage, G.R., III, Mayer, K.H., & Horsburgh, C.R., Jr. (1993). Risk of human immunodeficiency virus infection from unprotected receptive anal intercourse increases with decline in immunologic status of infected partners. American Journal of Epidemiology, 337(8), 899-908.
20. Tengs, T.O., Adams, M.E., Pliskin, J.F., Safran, D.G., Siegel, J.E., Weinstein, M.C., et al. (1995). Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis, 35, 369-390.
21. Unrecognized HIV infection, risk behaviors, and perceptions of risk among young black men who have sex with men-six U.S. cities, 1994-1998. (2002). Morbidity & Mortality Weekly Report, 53(33), 733-736.
22. U.S. Department of Health and Human Services/Health Resources and Services Administration. Programs: Youth and HIV/AIDS. Retrieved June 10, 2003, from http://hab.hrsa.gov/programs/factsheets/youthfact.htm
23. Vanable, P.A., Ostrow, D.G., McKirnan, D.J., Taywaditep, K.J., & Hope, B.A. (2000). Impact of combination therapies on HIV risk perceptions and sexual risk among HIV-positive and HIV-negative gay and bisexual men. Health Psychology, 39(2), 134-145.
24. World Health Organization. (2002, July). Young people and HIV/AIDS: opportunity in crisis-a joint report by UNICEF, UNAIDS and WHO. Paper presented at the 14th International Conference on AIDS, Barcelona, Spain.